



## Clinical trial results:

### A Phase 1 Open-label Study to Assess the Safety and Tolerability of a Single Dose of 13-valent Pneumococcal Conjugate Vaccine in Healthy Chinese Adults, Children and Infants

#### Summary

EudraCT number	2014-004180-20
Trial protocol	Outside EU/EEA
Global end of trial date	06 January 2012

#### Results information

Result version number	v1 (current)
This version publication date	29 June 2016
First version publication date	17 July 2015

#### Trial information

##### Trial identification

Sponsor protocol code	B1851046
-----------------------	----------

##### Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT01531322
WHO universal trial number (UTN)	-
Other trial identifiers	Alias: 6096A1-1000

Notes:

##### Sponsors

Sponsor organisation name	Pfizer Inc.
Sponsor organisation address	235 E 42nd Street, New York, United States, NY 10017
Public contact	Pfizer ClinicalTrials.gov Call Center, Pfizer Inc., 001 800-718-1021, ClinicalTrials.gov_Inquiries@pfizer.com
Scientific contact	Pfizer ClinicalTrials.gov Call Center, Pfizer Inc., 001 800-718-1021, ClinicalTrials.gov_Inquiries@pfizer.com

Notes:

##### Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	Yes

Notes:

## Results analysis stage

Analysis stage	Final
Date of interim/final analysis	24 July 2012
Is this the analysis of the primary completion data?	No
Global end of trial reached?	Yes
Global end of trial date	06 January 2012
Was the trial ended prematurely?	No

Notes:

## General information about the trial

Main objective of the trial:

To assess the safety and tolerability of a single dose of 13-valent pneumococcal conjugate vaccine (13vPnC) as measured by the incidence of solicited local reactions, systemic events, and unsolicited adverse events (AEs) in healthy Chinese subjects in 3 age groups: Group 1: Adults aged 18 through 55 years, Group 2: Children aged 3 through 5 years, Group 3: Infants aged approximately 2 months.

Protection of trial subjects:

The study was in compliance with the ethical principles derived from the Declaration of Helsinki and in compliance with all International Conference on Harmonization (ICH) Good Clinical Practice (GCP) Guidelines. All the local regulatory requirements pertinent to safety of trial subjects were followed.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	19 October 2011
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	No

Notes:

## Population of trial subjects

### Subjects enrolled per country

Country: Number of subjects enrolled	China: 72
Worldwide total number of subjects	72
EEA total number of subjects	0

Notes:

### Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	24
Children (2-11 years)	24
Adolescents (12-17 years)	0
Adults (18-64 years)	24
From 65 to 84 years	0
85 years and over	0

## Subject disposition

### Recruitment

Recruitment details: -

### Pre-assignment

Screening details:

The study was started on 19 Oct 2011 and completed on 06 Jan 2012 in China.

### Period 1

Period 1 title	Overall Study (overall period)
Is this the baseline period?	Yes
Allocation method	Not applicable
Blinding used	Not blinded

### Arms

Are arms mutually exclusive?	Yes
<b>Arm title</b>	13vPnC Group 1

Arm description:

Subjects aged 18 to 55 years received single 13vPnC dose on Day 1.

Arm type	Experimental
Investigational medicinal product name	13vPnC
Investigational medicinal product code	
Other name	Prevenar 13
Pharmaceutical forms	Injection
Routes of administration	Intramuscular use

Dosage and administration details:

Single 0.5 milliliter (mL) dose of 13vPnC administered intramuscularly on Day 1.

<b>Arm title</b>	13vPnC Group 2
------------------	----------------

Arm description:

Subjects aged 3 to 5 years received single 13vPnC dose on Day 1.

Arm type	Experimental
Investigational medicinal product name	13vPnC
Investigational medicinal product code	
Other name	Prevenar 13
Pharmaceutical forms	Injection
Routes of administration	Intramuscular use

Dosage and administration details:

Single 0.5 mL dose of 13vPnC administered intramuscularly on Day 1.

<b>Arm title</b>	13vPnC Group 3
------------------	----------------

Arm description:

Subjects aged 2 months (42 to 98 days) received single 13vPnC dose on Day 1.

Arm type	Experimental
Investigational medicinal product name	13vPnC
Investigational medicinal product code	
Other name	Prevenar 13
Pharmaceutical forms	Injection
Routes of administration	Intramuscular use

Dosage and administration details:

Single 0.5 mL dose of 13vPnC administered intramuscularly on Day 1.

<b>Number of subjects in period 1</b>	13vPnC Group 1	13vPnC Group 2	13vPnC Group 3
Started	24	24	24
Vaccinated	24	24	24
Completed	24	24	24

## Baseline characteristics

### Reporting groups

Reporting group title	13vPnC Group 1
Reporting group description:	
Subjects aged 18 to 55 years received single 13vPnC dose on Day 1.	
Reporting group title	13vPnC Group 2
Reporting group description:	
Subjects aged 3 to 5 years received single 13vPnC dose on Day 1.	
Reporting group title	13vPnC Group 3
Reporting group description:	
Subjects aged 2 months (42 to 98 days) received single 13vPnC dose on Day 1.	

Reporting group values	13vPnC Group 1	13vPnC Group 2	13vPnC Group 3
Number of subjects	24	24	24
Age categorical			
Units: Subjects			
18 years - 55 years	24	0	0
3 years - 5 years	0	24	0
42 days - 98 days	0	0	24
Gender categorical			
Units: Subjects			
Female	11	11	8
Male	13	13	16

Reporting group values	Total		
Number of subjects	72		
Age categorical			
Units: Subjects			
18 years - 55 years	24		
3 years - 5 years	24		
42 days - 98 days	24		
Gender categorical			
Units: Subjects			
Female	30		
Male	42		

## End points

### End points reporting groups

Reporting group title	13vPnC Group 1
Reporting group description: Subjects aged 18 to 55 years received single 13vPnC dose on Day 1.	
Reporting group title	13vPnC Group 2
Reporting group description: Subjects aged 3 to 5 years received single 13vPnC dose on Day 1.	
Reporting group title	13vPnC Group 3
Reporting group description: Subjects aged 2 months (42 to 98 days) received single 13vPnC dose on Day 1.	

### Primary: Number of Subjects With Treatment-Emergent Adverse Events (AEs) or Serious Adverse Events (SAEs)

End point title	Number of Subjects With Treatment-Emergent Adverse Events (AEs) or Serious Adverse Events (SAEs) <sup>[1]</sup>
End point description: An AE was any untoward medical occurrence in a subject who received study drug without regard to possibility of causal relationship. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent are events between first dose of study drug and up to one month after last dose that were absent before treatment or that worsened relative to pretreatment state. AEs included both SAEs and non-SAEs. The safety analysis population included all subjects who received at least 1 dose of investigational product.	
End point type	Primary
End point timeframe: Within 1 month after 13vPnC Dose	
Notes: [1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point. Justification: Only descriptive data was planned to be reported for this endpoint.	

End point values	13vPnC Group 1	13vPnC Group 2	13vPnC Group 3	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	24	24	24	
Units: Subjects				
AE	0	0	1	
SAE	0	0	1	

### Statistical analyses

No statistical analyses for this end point

### Primary: Percentage of Subjects Reporting Pre-Specified Local Reactions

End point title	Percentage of Subjects Reporting Pre-Specified Local
-----------------	--

End point description:

Local reactions reported by electronic diary(e-diary).Redness,swelling scaled as:any(present); mild(13vPnC Group1: 2.5--5.0 centimeters[cm],13vPnC Group2,3: 0.5--2.0 cm);moderate(Group1:more than[>]5.0--10.0 cm,Group2,3:>2.0--7.0 cm)and severe(Group1:>10.0 cm, Group2,3:>7.0 cm)and necrosis or exfoliative dermatitis.Pain assessed only for Group1 as:any(any pain);mild(does not interfere with activity);moderate(interferes with activity);severe(prevents daily activity) and emergency room(ER)or Hospitalized(required ER visit or hospitalization).ER visit for 1 subject due to pain at injection site was reported in error.Tenderness was assessed for Group2,3 and scaled as:any(any grade of tenderness);present(tenderness present)and interferes with limb movement.Subjects may be represented in more than 1 category.Safety analysis population analyzed.Here"99999"for number and"+/--99999"for confidence interval signifies"not available"as data was not planned to be analyzed for that reporting arms

End point type	Primary
----------------	---------

End point timeframe:

Within 7 Days after 13vPnC Dose

Notes:

[2] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Only descriptive data was planned to be reported for this endpoint.

End point values	13vPnC Group 1	13vPnC Group 2	13vPnC Group 3	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	24	24	24	
Units: Percentage of Subjects				
number (confidence interval 95%)				
Redness: Any	16.7 (4.7 to 37.4)	16.7 (4.7 to 37.4)	12.5 (2.7 to 32.4)	
Redness: Mild	12.5 (2.7 to 32.4)	8.3 (1 to 27)	12.5 (2.7 to 32.4)	
Redness: Moderate	12.5 (2.7 to 32.4)	8.3 (1 to 27)	0 (0 to 14.2)	
Redness: Severe	0 (0 to 14.2)	0 (0 to 14.2)	0 (0 to 14.2)	
Redness: Necrosis or exfoliative dermatitis	0 (0 to 14.2)	99999 (-99999 to 99999)	99999 (-99999 to 99999)	
Swelling: Any	16.7 (4.7 to 37.4)	29.2 (12.6 to 51.1)	25 (9.8 to 46.7)	
Swelling: Mild	12.5 (2.7 to 32.4)	20.8 (7.1 to 42.2)	16.7 (4.7 to 37.4)	
Swelling: Moderate	12.5 (2.7 to 32.4)	20.8 (7.1 to 42.2)	8.3 (1 to 27)	
Swelling: Severe	0 (0 to 14.2)	0 (0 to 14.2)	0 (0 to 14.2)	
Swelling: Necrosis or exfoliative dermatitis	0 (0 to 14.2)	99999 (-99999 to 99999)	99999 (-99999 to 99999)	
Pain at injection site: Any	95.8 (78.9 to 99.9)	99999 (-99999 to 99999)	99999 (-99999 to 99999)	
Pain at injection site: Mild	95.8 (78.9 to 99.9)	99999 (-99999 to 99999)	99999 (-99999 to 99999)	
Pain at injection site: Moderate	12.5 (2.7 to 32.4)	99999 (-99999 to 99999)	99999 (-99999 to 99999)	
Pain at injection site: Severe	0 (0 to 14.2)	99999 (-99999 to 99999)	99999 (-99999 to 99999)	
Pain at injection site: ER or Hospitalized	4.2 (0.1 to 21.1)	99999 (-99999 to 99999)	99999 (-99999 to 99999)	
Tenderness: Any	99999 (-99999 to 99999)	75 (53.3 to 90.2)	12.5 (2.7 to 32.4)	
Tenderness: Present	99999 (-99999 to 99999)	75 (53.3 to 90.2)	12.5 (2.7 to 32.4)	
Tenderness: Interferes with limb movement	99999 (-99999 to 99999)	0 (0 to 14.2)	0 (0 to 14.2)	

## Statistical analyses

No statistical analyses for this end point

### Primary: Percentage of Subjects Reporting Pre-Specified Systemic Events for 13vPnC Group 1

End point title	Percentage of Subjects Reporting Pre-Specified Systemic Events for 13vPnC Group 1 <sup>[3]</sup> <sup>[4]</sup>
-----------------	---

End point description:

Systemic events involved any fever greater than or equal to ( $\geq$ ) 37.7 degrees Celsius (C) as per State Food and Drug Administration (SFDA) China or  $\geq$ 38.0 degrees C to  $>$ 40.0 degrees C. Vomiting was scaled as= mild: 1 to 2 times in 24 hours (hrs), moderate:  $>$ 2 times in 24 hrs, severe: required intravenous (IV) hydration, ER or hospitalized: required an ER visit or hospitalization. Diarrhea was scaled as= mild: 2 to 3 loose stools in 24 hrs, moderate: 4 to 5 loose stools in 24 hrs, severe: 6 or more loose stools in 24 hrs. Headache, fatigue, muscle pain and joint pain were scaled as= mild: does not interfere with activity; moderate: some interference with activity; severe: prevents daily routine activity. Use of antipyretic medication was collected using an e-diary. Antipyretic medications used by 2 subjects was reported in error. The safety analysis population included all subjects who received at least 1 dose of investigational product.

End point type	Primary
----------------	---------

End point timeframe:

Within 7 days after 13vPnC Dose

Notes:

[3] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Only descriptive data was planned to be reported for this endpoint.

[4] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification:

Percentage of subjects reporting prepecified systemic events has been presented as separate endpoint for 13vPnC Group 1 and 13vPnC Group 2/13vPnC Group 3.

End point values	13vPnC Group 1			
Subject group type	Reporting group			
Number of subjects analysed	24			
Units: Percentage of Subjects				
number (confidence interval 95%)				
Fever: $\geq$ 38.0 degrees C	4.2 (0.1 to 21.1)			
Fever: $\geq$ 38.0 degrees C but $\leq$ 38.4 degrees C	0 (0 to 14.2)			
Fever: $>$ 38.4 degrees C but $\leq$ 38.9 degrees C	4.2 (0.1 to 21.1)			
Fever: $>$ 38.9 degrees C but $\leq$ 40.0 degrees C	0 (0 to 14.2)			
Fever: $>$ 40.0 degrees C	0 (0 to 14.2)			
Fever-SFDA: $\geq$ 37.7 degrees C	4.2 (0.1 to 21.1)			
Fever-SFDA: $\geq$ 37.7 degrees C but $\leq$ 38.5 degrees	4.2 (0.1 to 21.1)			



Fever-SFDA: $\geq 38.6$ degrees C but $\leq 39.5$ degrees	0 (0 to 14.2)			
Fever-SFDA: $\geq 39.6$ degrees C but $\leq 40.5$ degrees C	0 (0 to 14.2)			
Fever-SFDA: $> 40.0$ degrees C	0 (0 to 14.2)			
Vomiting: Any	0 (0 to 14.2)			
Vomiting: Mild	0 (0 to 14.2)			
Vomiting: Moderate	0 (0 to 14.2)			
Vomiting: Severe	0 (0 to 14.2)			
Vomiting: ER or hospitalized	0 (0 to 14.2)			
Diarrhea: Any	0 (0 to 14.2)			
Diarrhea: Mild	0 (0 to 14.2)			
Diarrhea: Moderate	0 (0 to 14.2)			
Diarrhea: Severe	0 (0 to 14.2)			
Diarrhea: ER or hospitalized	0 (0 to 14.2)			
Headache: Any	4.2 (0.1 to 21.1)			
Headache: Mild	4.2 (0.1 to 21.1)			
Headache: Moderate	0 (0 to 14.2)			
Headache: Severe	0 (0 to 14.2)			
Headache: ER or hospitalized	0 (0 to 14.2)			
Fatigue: Any	12.5 (2.7 to 32.4)			
Fatigue: Mild	12.5 (2.7 to 32.4)			
Fatigue: Moderate	0 (0 to 14.2)			
Fatigue: Severe	0 (0 to 14.2)			
Fatigue: ER or hospitalized	0 (0 to 14.2)			
Muscle pain: Any	20.8 (7.1 to 42.2)			
Muscle pain: Mild	20.8 (7.1 to 42.2)			
Muscle pain: Moderate	8.3 (1 to 27)			
Muscle pain: Severe	0 (0 to 14.2)			
Muscle pain: ER or hospitalized	0 (0 to 14.2)			
Joint pain: Any	4.2 (0.1 to 21.1)			
Joint pain: Mild	4.2 (0.1 to 21.1)			
Joint pain: Moderate	0 (0 to 14.2)			
Joint pain: Severe	0 (0 to 14.2)			
Joint pain: ER or hospitalized	0 (0 to 14.2)			
Use of antipyretic medications	8.3 (1 to 27)			

## Statistical analyses

No statistical analyses for this end point

## Primary: Percentage of Subjects Reporting Pre-Specified Systemic Events for 13vPnC Group 2 and 13vPnC Group 3

End point title	Percentage of Subjects Reporting Pre-Specified Systemic Events for 13vPnC Group 2 and 13vPnC Group 3 <sup>[5][6]</sup>
-----------------	--

---

**End point description:**

Systemic events included: any fever  $\geq 38.0$  degrees C, decreased appetite, irritability, increased sleep and decreased sleep. These were reported on each day. The use of antipyretic medication was reported in e-diary. The safety analysis population included all subjects who received at least 1 dose of investigational product.

---

End point type	Primary
----------------	---------

---

**End point timeframe:**

Within 7 days after 13vPnC Dose

---

**Notes:**

[5] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Only descriptive data was planned to be reported for this endpoint.

[6] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

**Justification:**

Percentage of subjects reporting prepecified systemic events has been presented as separate endpoint for 13vPnC Group 1 and 13vPnC Group 2/13vPnC Group 3.

End point values	13vPnC Group 2	13vPnC Group 3		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	24	24		
Units: Percentage of Subjects				
number (confidence interval 95%)				
Fever: $\geq 38.0$ degrees C	0 (0 to 14.2)	0 (0 to 14.2)		
Fever: $\geq 38.0$ degrees C but $\leq 39.0$ degrees C	0 (0 to 14.2)	0 (0 to 14.2)		
Fever: $> 39.0$ degrees C but $\leq 40.0$ degrees C	0 (0 to 14.2)	0 (0 to 14.2)		
Fever: $> 40.0$ degrees C	0 (0 to 14.2)	0 (0 to 14.2)		
Decreased appetite	0 (0 to 14.2)	0 (0 to 14.2)		
Irritability	0 (0 to 14.2)	12.5 (2.7 to 32.4)		
Increased sleep	4.2 (0.1 to 21.1)	12.5 (2.7 to 32.4)		
Decreased sleep	0 (0 to 14.2)	16.7 (4.7 to 37.4)		
Use of antipyretic medications	0 (0 to 14.2)	0 (0 to 14.2)		

---

**Statistical analyses**

No statistical analyses for this end point

---

## Adverse events

### Adverse events information

Timeframe for reporting adverse events:

Adverse events (AEs)/serious AEs (SAEs): Within 1 month after 13vPnC Dose.

Pre-specified AEs (local reactions, systemic events): Within 7 days after 13vPnC Dose

Adverse event reporting additional description:

SAEs, AEs grouped by system organ class and summarized. AEs included AEs collected in e-diary (local, systemic reactions; systematic assessment), events collected on case report form (non-systematic assessment).

Assessment type	Systematic
-----------------	------------

### Dictionary used

Dictionary name	MedDRA
-----------------	--------

Dictionary version	13.1
--------------------	------

### Reporting groups

Reporting group title	13vPnC Group 1
-----------------------	----------------

Reporting group description:

Subjects aged 18 to 55 years received single 13vPnC dose on Day 1.

Reporting group title	13vPnC Group 3
-----------------------	----------------

Reporting group description:

Subjects aged 2 months (42 to 98 days) received single 13vPnC dose on Day 1.

Reporting group title	13vPnC Group 2
-----------------------	----------------

Reporting group description:

Subjects aged 3 to 5 years received single 13vPnC dose on Day 1.

Serious adverse events	13vPnC Group 1	13vPnC Group 3	13vPnC Group 2
Total subjects affected by serious adverse events			
subjects affected / exposed	0 / 24 (0.00%)	1 / 24 (4.17%)	0 / 24 (0.00%)
number of deaths (all causes)	0	0	0
number of deaths resulting from adverse events	0	0	0
Infections and infestations			
Bronchopneumonia			
alternative assessment type: Non-systematic			
subjects affected / exposed	0 / 24 (0.00%)	1 / 24 (4.17%)	0 / 24 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Frequency threshold for reporting non-serious adverse events: 0 %

Non-serious adverse events	13vPnC Group 1	13vPnC Group 3	13vPnC Group 2
Total subjects affected by non-serious adverse events			
subjects affected / exposed	23 / 24 (95.83%)	9 / 24 (37.50%)	18 / 24 (75.00%)
General disorders and administration site conditions			
Fever: $\geq 38.0$ degrees C	Additional description: Subjects affected and occurrences for LRs and SEs is same as e-diaries could not distinguish 1 occurrence from another within a subject/vaccination. Dictionary version not captured, hence 0.0 is mentioned. This was not assessed for Group 2 and 3.		
alternative dictionary used: Systemic Events 0.0			
subjects affected / exposed	1 / 24 (4.17%)	0 / 24 (0.00%)	0 / 24 (0.00%)
occurrences (all)	1	0	0
Fever: $> 38.4$ degrees C but $\leq 38.9$ degrees C	Additional description: Subjects affected and occurrences for LRs and SEs is same as e-diaries could not distinguish 1 occurrence from another within a subject/vaccination. Dictionary version not captured, hence 0.0 is mentioned. This was not assessed for Group 2 and 3.		
alternative dictionary used: Systemic Events 0.0			
subjects affected / exposed	1 / 24 (4.17%)	0 / 24 (0.00%)	0 / 24 (0.00%)
occurrences (all)	1	0	0
Fever Grades by SFDA: $\geq 37.7$ degrees C	Additional description: Subjects affected and occurrences for LRs and SEs is same as e-diaries could not distinguish 1 occurrence from another within a subject/vaccination. Dictionary version not captured, hence 0.0 is mentioned. This was not assessed for Group 2 and 3.		
alternative dictionary used: Systemic Events 0.0			
subjects affected / exposed	1 / 24 (4.17%)	0 / 24 (0.00%)	0 / 24 (0.00%)
occurrences (all)	1	0	0
Fever Grades by SFDA: $\geq 37.7$ degrees C but $\leq 38.5$ degrees C	Additional description: Subjects affected and occurrences for LRs and SEs is same as e-diaries could not distinguish 1 occurrence from another within a subject/vaccination. Dictionary version not captured, hence 0.0 is mentioned. This was not assessed for Group 2 and 3.		
alternative dictionary used: Systemic Events 0.0			
subjects affected / exposed	1 / 24 (4.17%)	0 / 24 (0.00%)	0 / 24 (0.00%)
occurrences (all)	1	0	0
Headache: Any	Additional description: Subjects affected and occurrences for LRs and SEs is same as e-diaries could not distinguish 1 occurrence from another within a subject/vaccination. Dictionary version not captured, hence 0.0 is mentioned. This was not assessed for Group 2 and 3.		
alternative dictionary used: Systemic Events 0.0			
subjects affected / exposed	1 / 24 (4.17%)	0 / 24 (0.00%)	0 / 24 (0.00%)
occurrences (all)	1	0	0
Headache: Mild	Additional description: Subjects affected and occurrences for LRs and SEs is same as e-diaries could not distinguish 1 occurrence from another within a subject/vaccination. Dictionary version not captured, hence 0.0 is mentioned. This was not assessed for Group 2 and 3.		
alternative dictionary used: Systemic Events 0.0			
subjects affected / exposed	1 / 24 (4.17%)	0 / 24 (0.00%)	0 / 24 (0.00%)
occurrences (all)	1	0	0
Fatigue: Any	Additional description: Subjects affected and occurrences for LRs and SEs is		

same as e-diaries could not distinguish 1 occurrence from another within a subject/vaccination. Dictionary version not captured, hence 0.0 is mentioned. This was not assessed for Group 2 and 3.			
alternative dictionary used: Systemic Events 0.0 subjects affected / exposed occurrences (all)	3 / 24 (12.50%) 3	0 / 24 (0.00%) 0	0 / 24 (0.00%) 0
Fatigue: Mild	Additional description: Subjects affected and occurrences for LRs and SEs is same as e-diaries could not distinguish 1 occurrence from another within a subject/vaccination. Dictionary version not captured, hence 0.0 is mentioned. This was not assessed for Group 2 and 3.		
alternative dictionary used: Systemic Events 0.0 subjects affected / exposed occurrences (all)	3 / 24 (12.50%) 3	0 / 24 (0.00%) 0	0 / 24 (0.00%) 0
Muscle pain: Any	Additional description: Subjects affected and occurrences for LRs and SEs is same as e-diaries could not distinguish 1 occurrence from another within a subject/vaccination. Dictionary version not captured, hence 0.0 is mentioned. This was not assessed for Group 2 and 3.		
alternative dictionary used: Systemic Events 0.0 subjects affected / exposed occurrences (all)	5 / 24 (20.83%) 5	0 / 24 (0.00%) 0	0 / 24 (0.00%) 0
Muscle pain: Mild	Additional description: Subjects affected and occurrences for LRs and SEs is same as e-diaries could not distinguish 1 occurrence from another within a subject/vaccination. Dictionary version not captured, hence 0.0 is mentioned. This was not assessed for Group 2 and 3.		
alternative dictionary used: Systemic Events 0.0 subjects affected / exposed occurrences (all)	5 / 24 (20.83%) 5	0 / 24 (0.00%) 0	0 / 24 (0.00%) 0
Muscle pain: Moderate	Additional description: Subjects affected and occurrences for LRs and SEs is same as e-diaries could not distinguish 1 occurrence from another within a subject/vaccination. Dictionary version not captured, hence 0.0 is mentioned. This was not assessed for Group 2 and 3.		
alternative dictionary used: Systemic Events 0.0 subjects affected / exposed occurrences (all)	2 / 24 (8.33%) 2	0 / 24 (0.00%) 0	0 / 24 (0.00%) 0
Joint pain: Any	Additional description: Subjects affected and occurrences for LRs and SEs is same as e-diaries could not distinguish 1 occurrence from another within a subject/vaccination. Dictionary version not captured, hence 0.0 is mentioned. This was not assessed for Group 2 and 3.		
alternative dictionary used: Systemic Events 0.0 subjects affected / exposed occurrences (all)	1 / 24 (4.17%) 1	0 / 24 (0.00%) 0	0 / 24 (0.00%) 0
Joint pain: Mild	Additional description: Subjects affected and occurrences for LRs and SEs is same as e-diaries could not distinguish 1 occurrence from another within a subject/vaccination. Dictionary version not captured, hence 0.0 is mentioned. This was not assessed for Group 2 and 3.		
alternative dictionary used: Systemic Events 0.0 subjects affected / exposed occurrences (all)	1 / 24 (4.17%) 1	0 / 24 (0.00%) 0	0 / 24 (0.00%) 0

Irritability	Additional description: Subjects affected and occurrences for LRs and SEs is same as e--diaries could not distinguish 1 occurrence from another within a subject/vaccination. Dictionary version not captured, hence 0.0 is mentioned. This was not assessed for Group 1.		
	alternative dictionary used: Systemic Events 0.0		
	subjects affected / exposed occurrences (all)	0 / 24 (0.00%) 0	3 / 24 (12.50%) 3 0 / 24 (0.00%) 0
Increased sleep	Additional description: Subjects affected and occurrences for LRs and SEs is same as e--diaries could not distinguish 1 occurrence from another within a subject/vaccination. Dictionary version not captured, hence 0.0 is mentioned. This was not assessed for Group 1.		
	alternative dictionary used: Systemic Events 0.0		
	subjects affected / exposed occurrences (all)	0 / 24 (0.00%) 0	3 / 24 (12.50%) 3 1 / 24 (4.17%) 1
Decreased sleep	Additional description: Subjects affected and occurrences for LRs and SEs is same as e--diaries could not distinguish 1 occurrence from another within a subject/vaccination. Dictionary version not captured, hence 0.0 is mentioned. This was not assessed for Group 1.		
	alternative dictionary used: Systemic Events 0.0		
	subjects affected / exposed occurrences (all)	0 / 24 (0.00%) 0	4 / 24 (16.67%) 4 0 / 24 (0.00%) 0
Skin and subcutaneous tissue disorders			
	Redness: Any	Additional description: Subjects affected and occurrences for LRs and SEs is same as data collected through e-diaries cannot be used to distinguish one occurrence from another within a subject/vaccination.	
	alternative dictionary used: Local Reactions 0.0		
	subjects affected / exposed occurrences (all)	4 / 24 (16.67%) 4	3 / 24 (12.50%) 3 4 / 24 (16.67%) 4
	Redness: Mild	Additional description: Subjects affected and occurrences for LRs and SEs is same as data collected through e-diaries cannot be used to distinguish one occurrence from another within a subject/vaccination. Version not captured, here 0.0 is mentioned for dictionary version.	
	alternative dictionary used: Local Reactions 0.0		
	subjects affected / exposed occurrences (all)	3 / 24 (12.50%) 3	3 / 24 (12.50%) 3 2 / 24 (8.33%) 2
Redness: Moderate	Additional description: Subjects affected and occurrences for LRs and SEs is same as data collected through e-diaries cannot be used to distinguish one occurrence from another within a subject/vaccination. Version not captured, here 0.0 is mentioned for dictionary version.		
	alternative dictionary used: Local Reactions 0.0		
	subjects affected / exposed occurrences (all)	2 / 24 (8.33%) 3	0 / 24 (0.00%) 0 2 / 24 (8.33%) 2
Swelling: Any	Additional description: Subjects affected and occurrences for LRs and SEs is same as data collected through e-diaries cannot be used to distinguish one occurrence from another within a subject/vaccination. Version not captured, here 0.0 is mentioned for dictionary version.		
	alternative dictionary used: Local Reactions 0.0		

subjects affected / exposed	4 / 24 (16.67%)	6 / 24 (25.00%)	7 / 24 (29.17%)
occurrences (all)	4	6	7
Swelling: Mild	Additional description: Subjects affected and occurrences for LRs and SEs is same as data collected through e-diaries cannot be used to distinguish one occurrence from another within a subject/vaccination. Version not captured, here 0.0 is mentioned for dictionary version.		
alternative dictionary used: Local Reactions 0.0			
subjects affected / exposed	3 / 24 (12.50%)	4 / 24 (16.67%)	5 / 24 (20.83%)
occurrences (all)	3	4	5
Pain at injection site: Any	Additional description: Subjects affected and occurrences for LRs and SEs is same as e-diaries could not distinguish 1 occurrence from another within a subject/vaccination. Dictionary version not captured, hence 0.0 is mentioned. This was not assessed for Group 2 and 3.		
alternative dictionary used: Local Reactions 0.0			
subjects affected / exposed	23 / 24 (95.83%)	0 / 24 (0.00%)	0 / 24 (0.00%)
occurrences (all)	23	0	0
Pain at injection site: Mild	Additional description: Subjects affected and occurrences for LRs and SEs is same as e-diaries could not distinguish 1 occurrence from another within a subject/vaccination. Dictionary version not captured, hence 0.0 is mentioned. This was not assessed for Group 2 and 3.		
alternative dictionary used: Local Reactions 0.0			
subjects affected / exposed	23 / 24 (95.83%)	0 / 24 (0.00%)	0 / 24 (0.00%)
occurrences (all)	23	0	0
Pain at injection site: Moderate	Additional description: Subjects affected and occurrences for LRs and SEs is same as e-diaries could not distinguish 1 occurrence from another within a subject/vaccination. Dictionary version not captured, hence 0.0 is mentioned. This was not assessed for Group 2 and 3.		
alternative dictionary used: Local Reactions 0.0			
subjects affected / exposed	3 / 24 (12.50%)	0 / 24 (0.00%)	0 / 24 (0.00%)
occurrences (all)	3	0	0
Pain at injection site: ER or Hospitalized	Additional description: Subjects affected and occurrences for LRs and SEs is same as e-diaries could not distinguish 1 occurrence from another within a subject/vaccination. Dictionary version not captured, hence 0.0 is mentioned. This was not assessed for Group 2 and 3.		
alternative dictionary used: Local Reactions 0.0			
subjects affected / exposed	1 / 24 (4.17%)	0 / 24 (0.00%)	0 / 24 (0.00%)
occurrences (all)	1	0	0
Tenderness: Any	Additional description: Subjects affected and occurrences for LRs and SEs is same as e-diaries could not distinguish 1 occurrence from another within a subject/vaccination. Dictionary version not captured, hence 0.0 is mentioned. This was not assessed for Group 1.		
alternative dictionary used: Local Reactions 0.0			
subjects affected / exposed	0 / 24 (0.00%)	3 / 24 (12.50%)	18 / 24 (75.00%)
occurrences (all)	0	3	18
Tenderness: Present	Additional description: Subjects affected and occurrences for LRs and SEs is same as e-diaries could not distinguish 1 occurrence from another within a subject/vaccination. Dictionary version not captured, hence 0.0 is mentioned. This was not assessed for Group 1.		

alternative dictionary used: Local Reactions 0.0			
subjects affected / exposed	0 / 24 (0.00%)	3 / 24 (12.50%)	18 / 24 (75.00%)
occurrences (all)	0	3	18
Swelling: Moderate	Additional description: Subjects affected and occurrences for LRs and SEs is same as data collected through e-diaries cannot be used to distinguish one occurrence from another within a subject/vaccination. Version not captured, here 0.0 is mentioned for dictionary version.		
alternative dictionary used: Local Reactions 0.0			
subjects affected / exposed	3 / 24 (12.50%)	2 / 24 (8.33%)	5 / 24 (20.83%)
occurrences (all)	3	2	5



## More information

### Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
10 May 2011	1. Increased the observation period following vaccination from 20 minutes to 30 minutes.
18 October 2011	1. Added a category in the pain assessment, wherein subjects of Group 1 were asked in the e-diary to report whether the pain at the injection site required an emergency room (ER) visit or hospitalization. 2. Corrected the safety reporting period upto 1 month after the vaccination.

Notes:

---

### Interruptions (globally)

Were there any global interruptions to the trial? No

### Limitations and caveats

None reported